Opportunities with Phage Display
Phage display was invented and patented by Dyax scientists in the late 1980s.
This technology allows the display of many therapeutic candidate molecules on the surface of a small bacterial virus called a bacteriophage (phage). These molecules include:
- Human antibody fragments (Fabs)
- Small proteins (e.g. Kunitz domains)
A collection of displayed molecules is known as a library and can contain up to tens of billions of different molecules. Phage display enables Dyax to search through these libraries.
Dyax phage display can rapidly identify molecules that bind with high specificity and affinity to targets of therapeutic interest.
Dyax's automated screening methods have allowed us to streamline the screening of these libraries to isolate leads against therapeutic targets. These methods have led to two approved products and multiple candidates now in the clinic. Click Here to see the full licensee pipeline.